BR0315417A - Derivados 1-acil-pirrolidina para o tratamento de infecções virais - Google Patents

Derivados 1-acil-pirrolidina para o tratamento de infecções virais

Info

Publication number
BR0315417A
BR0315417A BR0315417-3A BR0315417A BR0315417A BR 0315417 A BR0315417 A BR 0315417A BR 0315417 A BR0315417 A BR 0315417A BR 0315417 A BR0315417 A BR 0315417A
Authority
BR
Brazil
Prior art keywords
treatment
alkyl
viral infections
aryl
pyrrolidine derivatives
Prior art date
Application number
BR0315417-3A
Other languages
English (en)
Portuguese (pt)
Inventor
David Haigh
Charles David Hartley
Peter David Howes
Deborah Lynette Jackson
Pritom Shah
Martin John Slater
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0224774A external-priority patent/GB0224774D0/en
Priority claimed from GB0229470A external-priority patent/GB0229470D0/en
Priority claimed from GB0317141A external-priority patent/GB0317141D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR0315417A publication Critical patent/BR0315417A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
BR0315417-3A 2002-10-24 2003-10-22 Derivados 1-acil-pirrolidina para o tratamento de infecções virais BR0315417A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0224774A GB0224774D0 (en) 2002-10-24 2002-10-24 Compounds
GB0229470A GB0229470D0 (en) 2002-12-18 2002-12-18 Compounds
GB0317141A GB0317141D0 (en) 2003-07-22 2003-07-22 Compounds
PCT/EP2003/011813 WO2004037818A1 (en) 2002-10-24 2003-10-22 1-acyl-pyrrolidine derivatives for the treatment of viral infections

Publications (1)

Publication Number Publication Date
BR0315417A true BR0315417A (pt) 2005-08-16

Family

ID=32180212

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315417-3A BR0315417A (pt) 2002-10-24 2003-10-22 Derivados 1-acil-pirrolidina para o tratamento de infecções virais

Country Status (18)

Country Link
US (1) US7304087B2 (https=)
EP (1) EP1554274B1 (https=)
JP (1) JP2006506455A (https=)
KR (1) KR20050057670A (https=)
AR (1) AR041816A1 (https=)
AT (1) ATE418554T1 (https=)
AU (1) AU2003276172A1 (https=)
BR (1) BR0315417A (https=)
CA (1) CA2503471A1 (https=)
CO (1) CO5550450A2 (https=)
DE (1) DE60325498D1 (https=)
IS (1) IS7851A (https=)
MA (1) MA27524A1 (https=)
MX (1) MXPA05004435A (https=)
NO (1) NO20052472L (https=)
PL (1) PL376454A1 (https=)
TW (1) TW200418848A (https=)
WO (1) WO2004037818A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304494D0 (en) * 2003-02-27 2003-04-02 Glaxo Group Ltd Compounds
GB0408995D0 (en) * 2004-04-22 2004-05-26 Glaxo Group Ltd Compounds
GB0423673D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
GB0423672D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
JP4663733B2 (ja) * 2004-10-29 2011-04-06 シェーリング コーポレイション 抗ウイルス物質としての置換5−オキソピラゾールおよび置換[1,2,4]トリアゾール
GB0519478D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519488D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519486D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519485D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
PT2144604E (pt) 2007-02-28 2011-10-19 Conatus Pharmaceuticals Inc Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
ES2381410T3 (es) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC
US20090053175A1 (en) * 2007-08-24 2009-02-26 Yat Sun Or Substitute pyrrolidine derivatives
EP2272832A4 (en) 2008-04-28 2011-09-07 Asahi Kasei Pharma Corp PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF
JP2011530562A (ja) 2008-08-11 2011-12-22 グラクソスミスクライン エルエルシー アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
SI2320905T1 (sl) 2008-08-11 2017-10-30 Glaxosmithkline Llc Corporation Service Company Novi adeninski derivati
EP2534149B1 (en) 2010-02-10 2014-10-15 GlaxoSmithKline LLC 6-amino-2-{[(1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-one maleate
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
WO2013134012A1 (en) 2012-03-06 2013-09-12 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
MX2017006302A (es) 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
TWI704154B (zh) 2015-12-03 2020-09-11 英商葛蘭素史克智慧財產發展有限公司 新穎化合物
HRP20220936T1 (hr) 2016-04-07 2022-10-28 Glaxosmithkline Intellectual Property Development Limited Heterociklički amidi korisni kao modulatori proteina
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited タンパク質調節物質として有用な複素環アミド
US20210238172A1 (en) 2017-10-05 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators and methods of using the same
CA3077337A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
JP2022533194A (ja) 2019-05-16 2022-07-21 スティングセラ インコーポレイテッド ベンゾ[b][1,8]ナフチリジン酢酸誘導体および使用方法
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5687396A (en) 1995-04-21 1996-11-07 Novarits Ag N-aroylamino acid amides as endothelin inhibitors
AU1804299A (en) 1997-12-08 1999-06-28 Glycomed Incorporated Sialyl lewis x and sialyl lewis a glycomimetics
ATE391451T1 (de) 1998-01-26 2008-04-15 Massachusetts Inst Technology Endoskop zur erfassung von fluoreszenzbilder
EP1315698A1 (en) 1998-04-23 2003-06-04 Abbott Laboratories Pyrrolidines as inhibitors of neuraminidases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
EP1118287B1 (de) * 2000-01-21 2004-11-24 Alois Ing. Sampl Steckbares Regalsystem
EP1278743A4 (en) * 2000-05-05 2003-05-14 Smithkline Beecham Corp NEW ANTI-INFECTIOUS ACTIVE SUBSTANCES
WO2002044168A2 (en) 2000-11-20 2002-06-06 Scios Inc. Indole-type inhibitors of p38 kinase
BR0213760A (pt) 2001-10-26 2004-10-19 Upjohn Co Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
JP2005511572A (ja) 2001-11-02 2005-04-28 グラクソ グループ リミテッド Hcv阻害剤としてのアシルジヒドロピロール誘導体
CA2490385C (en) 2002-10-28 2014-05-06 Marquage Antivol Sherlock, Inc. Method of preventing theft of vehicles using intensive marking

Also Published As

Publication number Publication date
AR041816A1 (es) 2005-06-01
DE60325498D1 (de) 2009-02-05
PL376454A1 (en) 2005-12-27
ATE418554T1 (de) 2009-01-15
KR20050057670A (ko) 2005-06-16
CO5550450A2 (es) 2005-08-31
US20060258720A1 (en) 2006-11-16
EP1554274A1 (en) 2005-07-20
MA27524A1 (fr) 2005-09-01
US7304087B2 (en) 2007-12-04
TW200418848A (en) 2004-10-01
JP2006506455A (ja) 2006-02-23
AU2003276172A1 (en) 2004-05-13
EP1554274B1 (en) 2008-12-24
NO20052472L (no) 2005-05-23
WO2004037818A1 (en) 2004-05-06
CA2503471A1 (en) 2004-05-06
MXPA05004435A (es) 2005-07-26
IS7851A (is) 2005-05-19

Similar Documents

Publication Publication Date Title
BR0315417A (pt) Derivados 1-acil-pirrolidina para o tratamento de infecções virais
DE602007008616D1 (de) Verfahren zur herstellung von 4'-azidocytidinderivaten
BR0312129A (pt) Derivados de espiroindolinapiperidina
NO20062339L (no) Hepatitt C virus-inhibitoerer
TR200100438T2 (tr) Hepatit C inhibitörü peptitler
MEP24608A (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
ATE481106T1 (de) Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
BR0110998A (pt) Derivados de fenilglicina
ATE291923T1 (de) Veränderter faktor viii
IS7533A (is) Lifrarbólgu C-veirutálmar
DK1265606T3 (da) Celleadhæsionsinhibitorer
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
IS7531A (is) Skiptitengdir sýklóalkýl P1' lifrarbólgu C-veirutálmar
NO20062267L (no) Hepatitt C virus inhibitorer
DK1041072T3 (da) Dioxocyclopentylhydroxamsyrer
ATE423122T1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
NO20054340L (no) Nye sammenkoplede heterocykler og deres anvendelse
MA30904B1 (fr) Nouveaux derives du fluorene, compositions les contenant et utilisation comme inhibiteurs de la proteine chpaerone hsp90
ATE482933T1 (de) Sulfopyrrolderivate
HRP20070549T3 (en) Isoquinoline derivatives, process for their preparation and use thereof in the treatment of melatoninergic system problems
BR0314860A (pt) Derivados de pirazol
DE60131733D1 (de) Verfahren zur herstellung von (2s,3r,4s)-4-hydroxyisoleucin und analoga
BR0313000A (pt) Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente
DE602005010607D1 (de) Zyklosporinanalog

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.